Abstract:Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation and imbalances in lipid metabolism in the liver. Although nuclear receptors (NRs) play a crucial role in hepatic lipid metabolism, the underlying mechanisms of NR regulation in NAFLD remain largely unclear. Methods: Using network analysis and RNA-seq to determine the correlation between NRs and microRNA in human NAFLD patients, we revealed that MIR20B specifically targets PPARA. MIR20B mimic and anti-MIR20B were administered to human HepG2 and Huh-7 cells and mouse primary hepatocytes as well as high-fat diet (HFD)- or methionine-deficient diet (MCD)-fed mice to verify the specific function of MIR20B in NAFLD. We tested the inhibition of the therapeutic effect of a PPARα agonist, fenofibrate, by Mir20b and the synergic effect of combination of fenofibrate with anti-Mir20b in NAFLD mouse model. Results: We revealed that MIR20B specifically targets PPARA through miRNA regulatory network analysis of nuclear receptor genes in NAFLD. The expression of MIR20B was upregulated in free fatty acid (FA)-treated hepatocytes and the livers of both obesity-induced mice and NAFLD patients. Overexpression of MIR20B significantly increased hepatic lipid accumulation and triglyceride levels. Furthermore, MIR20B significantly reduced FA oxidation and mitochondrial biogenesis by targeting PPARA. In Mir20b-introduced mice, the effect of fenofibrate to ameliorate hepatic steatosis was significantly suppressed. Finally, inhibition of Mir20b significantly increased FA oxidation and uptake, resulting in improved insulin sensitivity and a decrease in NAFLD progression. Moreover, combination of fenofibrate and anti-Mir20b exhibited the synergic effect on improvement of NAFLD in MCD-fed mice. Conclusions: Taken together, our results demonstrate that the novel MIR20B targets PPARA, plays a significant role in hepatic lipid metabolism, and present an opportunity for the development of novel therapeutics for NAFLD. Funding: This research was funded by Korea Mouse Phenotyping Project (2016M3A9D5A01952411), the National Research Foundation of Korea (NRF) grant funded by the Korea government (2020R1F1A1061267, 2018R1A5A1024340, NRF-2021R1I1A2041463, 2020R1I1A1A01074940, 2016M3C9A394589324), and the Future-leading Project Research Fund (1.210034.01) of UNIST.

LncRNA-H19 Promotes Hepatic Lipogenesis by Directly Regulating Mir-130A/pparγ Axis in Non-Alcoholic Fatty Liver Disease.

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

MiR-103-3p Promotes Hepatic Steatosis to Aggravate Nonalcoholic Fatty Liver Disease by Targeting of ACOX1

Long non‐coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes

Mir-149 Controls Non-Alcoholic Fatty Liver by Targeting Fgf-21

Effect of Mirna-10b in Regulating Cellular Steatosis Level by Targeting Ppar-Alpha Expression, A Novel Mechanism for the Pathogenesis of Nafld

LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1

291-LB: Long Noncoding RNA H19 Improves Insulin Resistance in Skeletal Muscle by Regulating Heterogeneous Nuclear Ribonucleoprotein A1

Long non-coding RNA H19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1

Long Noncoding RNA Lnc-Hc Regulates PPARγ-Mediated Hepatic Lipid Metabolism Through Mir-130B-3p.

Lnc-Hc Ameliorates Steatosis by Promoting Mir-130B-3p Biogenesis and the Assembly of an RNA-induced Silencing Complex.

Long Non-Coding Rna Profiling In A Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight Into Pathogenesis

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

HIF-1α-upregulated lncRNA-H19 regulates lipid droplet metabolism through the AMPKα pathway in hepatic stellate cells

LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Inhibition of Mir-499-5p Expression Improves Nonalcoholic Fatty Liver Disease

Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA

LncRNA MALAT1 Promotes PPARα/CD36-Mediated Hepatic Lipogenesis in Nonalcoholic Fatty Liver Disease by Modulating Mir-206/Arnt Axis

Regulation of lipid droplet (LD) formation in hepatocytes via regulation of SREBP1c by non-coding RNAs

Mutation of Mir-21 Targets Endogenous Lipoprotein Receptor-Related Protein 6 and Nonalcoholic Fatty Liver Disease.